{"id":43879,"date":"2023-12-07T15:09:23","date_gmt":"2023-12-07T15:09:23","guid":{"rendered":"https:\/?p=43879"},"modified":"2023-12-07T15:09:23","modified_gmt":"2023-12-07T15:09:23","slug":"abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/","title":{"rendered":"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion"},"content":{"rendered":"<p>AbbVie Inc. (<a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/ABBV\">ABBV: NYE<\/a>) is said to be closing in on a significant deal to acquire Cerevel Therapeutics Holdings Inc. in a deal worth approximately $8.7 billion. Cerevel Therapeutics (<a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CERE\">CERE: NSD<\/a>) is a drug developer specializing in neurological conditions such as Parkinson&#8217;s.<\/p>\n<p>&nbsp;<\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/ABBV\" target=\"_blank\" rel=\"noopener\">ABBV Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"ABBV\" data-theme=\"wt_bg_trans\" data-uid=\"20542826306571df03d14d26571df03d14d3\" data-width=\"700\" >\n\t\t<\/script><\/p>\n<\/div>\n<p><!-- STA Widget END --><\/p>\n<h2><strong>Acquisition Details:<\/strong><\/h2>\n<p>AbbVie is currently negotiating to acquire Cerevel for around $45 per share, which would make Cerevel a wholly owned subsidiary of AbbVie. The acquisition would expand AbbVie&#8217;s product portfolio and strengthen its capabilities in catering to patients with neurological conditions.<\/p>\n<p>Cerevel Therapeutics, backed by private equity firm Bain Capital, has become a prominent player in the industry due to its expertise in neurological drug development. The acquisition of Cerevel would further solidify AbbVie&#8217;s position in the pharmaceutical market and position the company as a frontrunner in the development and commercialization of drugs in the neurological field.<\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/CERE\" target=\"_blank\" rel=\"noopener\">CERE Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"CERE\" data-theme=\"wt_bg_trans\" data-uid=\"15606658316571df1d67a7c6571df1d67a7d\" data-width=\"700\" >\n\t\t<\/script><\/p>\n<\/div>\n<p><!-- STA Widget END --><\/p>\n<p>AbbVie is renowned for its innovative pharmaceutical solutions and has a proven track record of delivering treatments for various health conditions. With Cerevel Therapeutics&#8217; specialized knowledge in neurological drug development, the acquisition represents a strategic fit for AbbVie&#8217;s growth strategy in this sector.<\/p>\n<p>&nbsp;<\/p>\n<h2>Speculation and Official Statements:<\/h2>\n<p>Although neither AbbVie nor Cerevel Therapeutics have officially commented on the potential deal at this time, market observers are eagerly waiting for an official statement from both parties to confirm the terms and specifics of the significant transaction.<\/p>\n<p>The acquisition of Cerevel Therapeutics would be a major milestone for AbbVie&#8217;s growth strategy, further strengthening the company&#8217;s position in the pharmaceutical market. With its proven track record and innovative pharmaceutical solutions, AbbVie is well-positioned to leverage Cerevel&#8217;s expertise in the neurological field to deliver even better treatments for patients in need.<\/p>\n<p>&nbsp;<\/p>\n<h2>Conclusion:<\/h2>\n<p data-pm-slice=\"1 1 []\">The potential acquisition of Cerevel Therapeutics by AbbVie Inc. for $8.7 billion would strengthen AbbVie&#8217;s position in the market, expand its product portfolio in neurological drug development market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Inc. (ABBV: NYE) is said to be closing in on a significant deal to acquire Cerevel Therapeutics Holdings Inc. in a deal worth approximately&#8230;<\/p>\n","protected":false},"author":17,"featured_media":43882,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-43879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AbbVie to acquire Cerevel Therapeutics for $8.7 Billion<\/title>\n<meta name=\"description\" content=\"AbbVie is closing a significant deal to acquire Cerevel Therapeutics for $8.7 billion, expanding its capabilities in drug development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion\" \/>\n<meta property=\"og:description\" content=\"AbbVie is closing a significant deal to acquire Cerevel Therapeutics for $8.7 billion, expanding its capabilities in drug development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-07T15:09:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/12\/AbbVie-to-acquire-Cerevel-Therapeutics-for-8.7-Billion.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion\",\"datePublished\":\"2023-12-07T15:09:23+00:00\",\"dateModified\":\"2023-12-07T15:09:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/\"},\"wordCount\":325,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/\",\"name\":\"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2023-12-07T15:09:23+00:00\",\"dateModified\":\"2023-12-07T15:09:23+00:00\",\"description\":\"AbbVie is closing a significant deal to acquire Cerevel Therapeutics for $8.7 billion, expanding its capabilities in drug development.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion","description":"AbbVie is closing a significant deal to acquire Cerevel Therapeutics for $8.7 billion, expanding its capabilities in drug development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/","og_locale":"en_US","og_type":"article","og_title":"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion","og_description":"AbbVie is closing a significant deal to acquire Cerevel Therapeutics for $8.7 billion, expanding its capabilities in drug development.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2023-12-07T15:09:23+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/12\/AbbVie-to-acquire-Cerevel-Therapeutics-for-8.7-Billion.jpg","type":"image\/jpeg"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion","datePublished":"2023-12-07T15:09:23+00:00","dateModified":"2023-12-07T15:09:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/"},"wordCount":325,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/","name":"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2023-12-07T15:09:23+00:00","dateModified":"2023-12-07T15:09:23+00:00","description":"AbbVie is closing a significant deal to acquire Cerevel Therapeutics for $8.7 billion, expanding its capabilities in drug development.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/abbvie-to-acquire-cerevel-therapeutics-for-8-7-billion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"AbbVie to acquire Cerevel Therapeutics for $8.7 Billion"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/43879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=43879"}],"version-history":[{"count":3,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/43879\/revisions"}],"predecessor-version":[{"id":43884,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/43879\/revisions\/43884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/43882"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=43879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=43879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=43879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}